Tumors related to the kidney, bladder, and prostate gland
Conditions
Interventions
Experimental group(Prostate cancer, Bladder cancer, Kidney cancer):Treated with the Nano-Molecular Imaging Diagnosis and Therapy Integrated Platform
Control group(Prostate cancer, Bladder cancer, Kidney cancer):Treated with conventional therapy (without using the Nano-Molecular Imaging Diagnosis and Therapy Integrated Platform)
Sponsors
Harbin Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 18 years old, gender not restricted; 2. Patients diagnosed with prostate cancer, bladder cancer or kidney cancer; 3. Patients who have undergone PET/CT examination; 4. Patients subsequently confirmed by pathological examination; 5. Patients receiving therapeutic radionuclide combined with immunotherapy; 6. Patients who agree to use their medical records and examination results for research; 7. Patients whose important medical records or examination results were previously missing but have been corrected.
Exclusion criteria
Exclusion criteria: 1. Patients who have recovered from major trauma (including surgery) within 4 weeks prior to receiving medical technology treatment; 2. Patients with severe systemic or local infections or other serious coexisting diseases; 3. Patients with abnormal immune function or who have recently used immunosuppressants, enhancers (including various vaccines), etc.; 4. Patients with autoimmune diseases, including rheumatoid arthritis, etc.; 5. Patients with poorly controlled arrhythmias, including atrial fibrillation; 6. Patients with cardiac insufficiency (NYHA standard II) in New York; 7. Patients with uncontrolled hypertension; 8. Patients with any history of allergy to the components of the imaging agent, including antibodies, or with allergic constitution; 9. Subjects positive for syphilis, HBV, HCV, and HIV; 10. Male and female subjects of childbearing age who cannot take effective contraceptive measures; 11. Pregnant or lactating women; 12. Patients with mental illness or related medical history; 13. Patients who cannot or are unable to undergo PET/CT scans; 14. Other patients that medical technicians consider not meeting the requirements for the relevant type of disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety indicators;Efficacy indicators.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging indicators;Molecular imaging indicators;Survival outcome indicators; | — |
Countries
China
Contacts
Public ContactKezheng Wang
Harbin Medical University Cancer Hospital
Outcome results
None listed